Lung Cancer — Viva Defence

Opening statement (SASPOP, delivered aloud)

"Ms Tran is a 52-year-old never-smoker with stage IV EGFR-mutant lung adenocarcinoma, eighteen months into an excellent response to first-line osimertinib, now with radiological progression in bone and liver while remaining clinically well. Her main problems are: acquired resistance to her targeted therapy; a limited metastatic burden with one new site that may represent oligoprogression; symptom control that remains good but will not stay that way without a plan; and the psychological whiplash of progression after a long good run. I would like to characterise her resistance mechanism with re-biopsy, decide between local therapy for oligoprogression and a systemic switch, and recalibrate her goals-of-care conversation to the new phase of her illness." [1]

Structured problem list

1. Acquired osimertinib resistance — expected, not exceptional: median progression-free survival on osimertinib was about 18–19 months in FLAURA, so she has had the median run [1].
2. Limited progression pattern — two bone lesions plus one new liver lesion: the distinction between oligoprogression and systemic progression drives whether local therapy can extend the current drug.
3. Never-smoker identity and stigma — patients like Ms Tran often carry "how did I get lung cancer?" and guilt-by-association; it shapes every conversation.
4. Evolving goals of care — the disease is incurable but controllable; each transition is an opportunity to re-anchor what matters to her [3].

Integrated management plan

• Re-biopsy at progression — tissue from the liver lesion if safely accessible (or liquid biopsy as complement): I am looking for a resistance mechanism with a directed next step — MET amplification, a targetable second-site mutation, or small-cell transformation, which would change the regimen class entirely. A negative liquid biopsy does not exclude a mechanism, so tissue is preferred when feasible [4].
• Distinguish oligoprogression from systemic progression — two progressing bone lesions in an otherwise controlled disease can be treated with local therapy (radiotherapy to progressing sites) while osimertinib continues; genuinely systemic progression with a new visceral lesion argues for a systemic switch — typically platinum–pemetrexed chemotherapy in driver-mutant disease after TKI resistance [1].
• CNS surveillance — EGFR-mutant disease has a high brain-metastasis propensity; osimertinib was chosen partly for its CNS penetration in FLAURA, and progression raises the question of intracranial status — brain MRI belongs in her restaging [1].
• Symptom and bone health — assess pain from the bone lesions, consider a bone-modifying agent, and treat radiotherapy-targeted symptoms early.
• Recalibrate the conversation — progression is the moment to revisit what she values, not the moment to introduce palliative care for the first time; that should already be running in parallel [3].

Probing questions with model answers

"Why did you choose osimertinib first-line rather than chemotherapy or an older TKI?" — "Because FLAURA showed osimertinib roughly doubled progression-free survival versus first-generation EGFR TKIs — 18.9 versus 10.2 months — with an overall-survival benefit and far better CNS penetration. The genotype-first principle itself comes from IPASS: gefitinib beat chemotherapy only in EGFR-mutant disease and was worse in unselected patients, so we test, then treat" [1] [2].

"She asks why she can't have 'the immunotherapy drug she's read about'." — "Driver-mutant lung cancers respond poorly to checkpoint inhibitors as a class, whatever the PD-L1 level, and giving immunotherapy before or around an EGFR TKI increases the risk of serious pneumonitis when the TKI is used. Her best immunotherapy-free run is the targeted sequence; if we exhaust targeted and chemo options, the conversation can be revisited with that evidence framed honestly." [1] [2].

"What will you do if the re-biopsy shows small-cell transformation?" — "Treat it as small-cell lung cancer — a platinum–etoposide backbone, because transformed disease behaves like SCLC: aggressive, chemosensitive initially, and managed with the SCLC rulebook rather than the targeted-therapy one. This is exactly why progression tissue matters; the transformation is invisible to imaging and to PD-L1." [4].

"When and how did you involve palliative care?" — "At diagnosis of metastatic disease, by name, as routine — because the Temel trial showed early palliative care integrated with oncology improved quality of life and mood, reduced aggressive end-of-life care, and extended median survival from 8.9 to 11.6 months. I frame it as an added layer that helps her live well on treatment, not a sign that treatment is failing." [3].

"She asks directly: how long do I have?" — "Honesty with a range and a reason: median survival for her molecular group is measured in years on modern targeted sequences, but individuals vary widely and resistance timing is unpredictable. I would anchor on what we can control — the next biopsy, the next decision, the things she wants to do while she is well — and offer to talk numbers in as much detail as she wants, checking what the question sits underneath: often it is a specific fear or plan." [3].

Communication points

• Acknowledge the never-smoker stigma explicitly: lung cancer is not a disease she earned, and EGFR-mutant disease in never-smokers is a distinct biology, not a lifestyle verdict [2].
• Progression conversations are a skill: name the change, name what is still controlled, and attach the next concrete step before leaving the room.
• Advance care planning revisited at each transition, while she is well enough to lead it — with palliative care already integrated [3].